As of today, I did small reallocation among portfolio companies purely based on valuations
- Sold 1% stake in IEX (1% position size) and added that 1% to INOX Leisure (2% position size)
- Sold 0.5% stake in HDFC (3% position size) and added that 0.5% stake to NESCO (4.5% position size).
Updated portfolio is below.
Companies | Weightage |
---|---|
HCL Technologies Ltd. | 6.00% |
I T C Ltd. | 6.00% |
PI Industries Ltd. | 6.00% |
Power Grid Corporation of India Ltd. | 6.00% |
Larsen & Toubro Ltd. | 6.00% |
Ajanta Pharmaceuticals Ltd. | 4.50% |
Kolte-Patil Developers Ltd. | 4.50% |
Ashiana Housing Ltd. | 4.50% |
NESCO Ltd. | 4.50% |
InterGlobe Aviation Ltd. | 4.00% |
Bajaj Auto Ltd. | 4.00% |
Suprajit Engineering Ltd. | 4.00% |
Lupin Ltd. | 3.50% |
Manappuram Finance Ltd. | 3.50% |
Housing Development Finance Corporation Ltd. | 3.00% |
HDFC Asset Management Company Ltd | 3.00% |
Reliance Nippon Asset Management Co | 3.00% |
CARE Ratings Ltd. | 3.00% |
Avanti Feeds Ltd. | 2.00% |
Cera Sanitaryware Ltd | 2.00% |
Infosys Ltd. | 2.00% |
National Aluminium Co. Ltd. | 2.00% |
NATCO Pharma Ltd. | 2.00% |
Wonderla Holidays Ltd. | 2.00% |
Maithan Alloys Ltd. | 2.00% |
Cadila Healthcare Ltd. | 2.00% |
Inox Leisure Ltd. | 2.00% |
Indian Energy Exchange Ltd. | 1.00% |
Biocon Ltd. | 1.00% |
Ashok Leyland Ltd. | 1.00% |
Cash | 0.00% |
Go up in the thread (somewhere) to read my thoughts about this, I have explained this in quite details.
I invest in companies that I understand, I dont take macro views and sectoral calls, unless a sector becomes very cheap (like residential real estate now, like pharma in 2019, like IT in 2017).
A better comparison for Alembic is Ajanta. Cadila is at a different growth stage, being much bigger than Alembic. I preferred Ajanta over Alembic because of their dominance in their Indian business, their diversified business line, their low exposure to US markets (as other pharma companies that I hold have lots of US exposure), and their debt free balance sheet.